*To the Editor*:

We read, with keen interest, the randomized clinical trial of intrapleural fibrinolytic therapy versus early medical thoracoscopy (MT) for the treatment of pleural infection, which was published in a recent issue of *AnnalsATS* ([@bib1]). We congratulate the authors for conducting a randomized study addressing an important clinical question. The authors have concluded that early medical thoracoscopy may have a role in the management of complicated pleural effusion and empyema, leading to a reduced hospital stay. However, some critical points regarding the reported results need careful consideration and further discussion.

The primary outcome chosen for the trial was the duration of hospital stay. This outcome measure is not ideal for a clinical question concerning the use of medical thoracoscopy. Other parameters, such as radiologic resolution or referral/need for surgery, would have been more meaningful for assessing the benefit of the intervention proposed ([@bib2], [@bib3]). Even though authors have used the duration of hospital stay as the primary outcome measure, there is no mention of discharge criteria, which should have been objectivized to maintain uniformity. In the inclusion criteria, it is mentioned that patients with not completely drained empyema were enrolled. Authors have not mentioned how long they waited for empyema to drain before enrollment. This time duration is vital because a delay in the intervention may be associated with the failure of the intervention. It is also not clear why the authors chose to put a small-size intercostal tube in all patients before randomization. In patients randomized to the MT arm, the initial tube placement could have been avoided because it has, probably, led to the placement of intercostal tube twice in patients undergoing MT (an initial tube of a small size followed by a large tube after MT).

Regarding the performance of the MT, the authors have not mentioned the sedation protocol used for the MT, as it will affect the patient discomfort, procedure duration, ability to complete the procedure, and success achievement in pleural clearance. The proportion of patients undergoing rigid versus semirigid medical thoracoscopy is also not clear. The instrument used may also affect the procedure performance and success ([@bib4]). The closed forceps used for adhesiolysis are usually large in case of rigid thoracoscope and may be more effective in comparison to thin forceps used with the semirigid instrument. Similarly, the use of a suction irrigation device may also affect the pleural clearance, and it cannot be routinely used for semirigid instruments. In the discussion, the authors have mentioned the utility of obtaining a pleural biopsy during MT to increase the microbiological yield. It is worth mentioning here that the pilot study quoted by the authors used ultrasound-guided pleural biopsies, which are feasible in the intrapleural fibrinolytic arm as well ([@bib5]). There is no added advantage of MT in obtaining a pleural biopsy to increase the microbiological yield when it can be safely performed under ultrasound guidance.

In view of these issues, we suggest that the trial results should be interpreted with caution while applying in routine clinical practice.
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